Document is current
Any future updates will be listed below
-
Authors
Gillberg, Linn
Ørskov, Andreas D.
Nasif, Ammar
Ohtani, Hitoshi
Madaj, Zachary
Hansen, Jakob W.
Rapin, Nicolas
Mogensen, Johanne B.
Liu, Minmin
Dufva, Inge H.
Lykkesfeldt, Jens
Hajkova, Petra
Jones, Peter A.
Grønbæk, Kirsten http://orcid.org/0000-0002-1535-9601
-
Funding
Funding for this research was provided by:
Van Andel Research Institute
Rigshospitalet
Novo Nordisk Fonden (NNF13OC0003435, NNF17CC0027852)
Kræftens Bekæmpelse (223-A13071-18-S68)
National Cancer Institute (R35CA209859)
- License Information
-
More Information
Article History
Received: 18 June 2019
Accepted: 5 September 2019
First Online: 17 October 2019
Ethics approval and consent to participate
: The study was approved by the regional ethics committee (H-16022249) and conducted in accordance with the declarations of Helsinki. All patients included in this study signed an informed consent form prior to participation.
: Not applicable.
: KG serves on advisory boards for Celgene, Otsuka Pharma, and Janssen pharma. PAJ is a paid consultant for ZYMO Corporation. ADØ, AN, HO, JBM, JL, JWH, IHD, LG, ML, NR, PH, and ZM declare no potential conflicts of interest.
